Ignite Creation Date:
2024-05-05 @ 11:44 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00127114
Status:
WITHDRAWN
Last Update Posted:
2017-08-14
First Post:
2005-08-03
Brief Title:
Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia FTD
Sponsor:
Johns Hopkins University
Organization:
Johns Hopkins University
Study Overview
Official Title:
Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia FTD
Status:
WITHDRAWN
Status Verified Date:
2017-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
No funding and exclusion criteria were to stringent
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this clinical trial is to test whether or not the medication amantadine is effective in reducing behavioral disturbances in patients with frontotemporal dementia
Detailed Description:
Behavioral disturbances are a major cause of morbidity in frontotemporal dementia FTD yet little is known about the effectiveness of medications to treat these disturbances Preliminary data suggests that the dopaminergic agent amantadine may reduce these disturbances This 6-week prospective randomized placebo-controlled trial will compare amantadine to placebo to assess its effectiveness in reducing behavioral symptoms
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None